Cost-effectiveness analysis of treatment timing considering the future entry of lower-cost generics for hepatitis C

Cost-effectiveness analysis of treatment timing considering the future entry of lower-cost generics for hepatitis C

Katherine Heath1,2 1Mathematical Ecology Research Group, Department of Zoology, University of Oxford, Oxford OX1 3PS, UK; 2New College, Oxford OX1 3BN, UK Background: Cost-benefit analyses are crucial to inform treatment policies, particularly when the cost of patented drugs is very high. The cost o...

Full description

Bibliographic Details
Main Author: Heath K
Format: Article
Language:English
Published: Dove Medical Press 2018-09-01
Series:ClinicoEconomics and Outcomes Research
Subjects:
ledipasvir
sofosbuvir
cost-per-QALY-gained
drug patent expiry
HCV
hepatitis C treatment
Online Access:https://www.dovepress.com/cost-effectiveness-analysis-of-treatment-timing-considering-the-future-peer-reviewed-article-CEOR

Internet

https://www.dovepress.com/cost-effectiveness-analysis-of-treatment-timing-considering-the-future-peer-reviewed-article-CEOR

Similar Items